Propanc Biopharma has announced a strategic financing agreement with Hexstone Capital, securing up to $100 million. This funding will support the biopharmaceutical company's clinical pipeline development and aims to expand its digital asset portfolio to $100 million or more over the next year. Hexstone Capital, known for its investments in digital assets like BTC, ETH, SOL, and DOGE, is backing Propanc's growth in the digital finance sector.
Propanc Biopharma Secures $100 Million Financing from Hexstone Capital
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.